Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Xanthine oxidoreductase: a novel target for obesity and metabolic diseases

Feb. 21, 2007

Metabolic to announce phase IIb results for AOD-9604

Feb. 21, 2007

Roche grants GSK rights to non-prescription orlistat

Feb. 21, 2007

Novel metabolic drugs described in recent patent literature

Feb. 21, 2007

Recent patents disclose novel treatments for diabetes

Feb. 20, 2007

Post hoc subgroup analysis for Chrysalin in fracture repair

Feb. 20, 2007

Gestiva reduces cervical shortening

Feb. 20, 2007

Ark Therapeutics discusses phase III Vitor study with regulatory agencies

Feb. 20, 2007

Recent patents report new therapeutic agents for metabolic disorders

Feb. 20, 2007

Lipomics to support Isis on metabolic drug testing

Feb. 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...